MARKET

LYRA

LYRA

Lyra Therapeutics, Inc.
NASDAQ
0.1050
+0.0059
+5.95%
After Hours: 0.1028 -0.0022 -2.10% 18:46 04/25 EDT
OPEN
0.0991
PREV CLOSE
0.0991
HIGH
0.1055
LOW
0.0991
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
5.65
52 WEEK LOW
0.0820
MARKET CAP
6.92M
P/E (TTM)
-0.0732
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LYRA last week (0414-0418)?
Weekly Report · 6d ago
Weekly Report: what happened at LYRA last week (0407-0411)?
Weekly Report · 04/14 10:49
Weekly Report: what happened at LYRA last week (0331-0404)?
Weekly Report · 04/07 10:49
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/31 22:55
Weekly Report: what happened at LYRA last week (0324-0328)?
Weekly Report · 03/31 10:58
Weekly Report: what happened at LYRA last week (0317-0321)?
Weekly Report · 03/24 10:48
Weekly Report: what happened at LYRA last week (0310-0314)?
Weekly Report · 03/17 10:57
Lyra Therapeutics Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 11:04
More
About LYRA
More
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Recently
Symbol
Price
%Change

Webull offers Lyra Therapeutics Inc stock information, including NASDAQ: LYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYRA stock methods without spending real money on the virtual paper trading platform.